Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Pargyline and Phenethylamines

supplement:

Phenethylamines

Research Papers that Mention the Interaction

Phenylethylamine concentrations are increased primarily by phenylalanine, its amino acid precursor and by such monoamine oxidase inhibitors as L-deprenyl and pargyline.
Progress in Neuro-Psychopharmacology and Biological Psychiatry  •  1984  |  View Paper
Acute pretreatment with either a Type A monoamine oxidase inhibitor (MAOI), clorgyline, or a Type B MAOI, pargyline , markedly reduced the dose of phenylethylamine (PEA) required to produce checking and a variety of other behavioral changes in rhesus monkeys.
Biological psychiatry  •  1980  |  View Paper
I-phenylethylamine and is preferentially inhibited by deprenyl (KNOLL & MAGYAR, 1972) and pargyline (SQUIRES, 1972).
Journal of neurochemistry  •  1979  |  View Paper
In the case of pargyline , a less selective MAO-B inhibitor, the preference in favour of phenylethylamine was less pronounced.
Naunyn-Schmiedeberg's Archives of Pharmacology  •  2004  |  View Paper
Chronic pargyline … phenylethylamine was added to chronic pargyline treatment, blinks increased from a base line of 16.8 +/- 7.6 blinks/90 sec to 37 +/- 15 ….2 +/- 2.8 blinks/90 sec. to 41.9 +/- 10.3 blinks/90 sec. and reversed a decrease in blinking caused by haloperidol.
Biological psychiatry  •  1981  |  View Paper
Abstract Pargyline , a slightly selective inhibitor of type B monoamine oxidase (MAO), inhibited phenylethylamine oxidation by 88 ± 1% and 81 ± 1% in rat brain and liver, respectively, at 24 hrs after injection of a 30 mg/kg i.p.
Life sciences  •  1978  |  View Paper
Deamination of phenylethylamine is inhibited approximately 70% by 10(-5) M pargyline and 30% by 10(-3) M semicarbazide.
The Journal of pharmacology and experimental therapeutics  •  1975  |  View Paper
The proportion of brain radioactivity due to β‐phenethylamine was increased by the monoamine oxidase inhibitor, pargyline , and was not affected by the peripheral decarboxylase inhibitor Ro 4–4602.
When Ro 4–4602 and pargyline were given together, the increase in radioactive phenethylamine produced by pargyline was prevented, suggesting that a significant proportion of brain phenethylamine may be synthesized in the periphery and can enter brain if monoamine oxidase is inhibited.
The Journal of pharmacy and pharmacology  •  1974  |  View Paper